the aid library

LIST OPTIONS

Filter

6391

WHO Expert Consultation on Rabies. 3rd report

Abela-Ridder, B. World Health Organisation (WHO) (2018) C_WHO

WHO TRS N°1012. Key updates include: (i) surveillance strategies, including cross-sectoral linking of systems and suitable diagnostics; (ii) the latest recommendations on human and animal immunization; (iii) palliative care in lowresource settings; (iv) risk assessment to guide management of bite... more

Download (779)

View PDF (1327)

Laboratory testing for Zika virus and dengue virus infections: interim guidance
recommended

World Health Organization (2022) C_WHO

Zika and dengue viruses remain significant public health threats. These viruses share the same Aedes (Stegomyia) mosquito vectors and geographic distributions but infections cannot be readily distinguished clinically and need to be differentiated from each other, and from other circulating arboviral... more

Download (253)

View PDF (248)

Prevention and control of noncommunicable diseases in Kyrgyzstan: the case for investment

World Health Organization WHO, Regional Office of Europe (2017) C_WHO

Noncommunicable diseases (‎NCDs)‎ such as cancer, cardiovascular diseases, diabetes and chronic respiratory diseases and their risk factors are an increasing public health and development challenge in Kyrgyzstan. This report provides evidence through three analyses that NCDs reduce economic outp... more

Download (646)

View PDF (730)

Mental Health and Psychosocial Support (MHPSS) in the context of the crises in Syria and Iraq

Sigmund Freud Privatuniversität; BAff; Charité; et al. Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH (2017) C2

Guiding framework for development cooperation, Working paper 2017. This document was drawn up on the basis of expert publications and inputs from partners in the GIZ regional programme Psychosocial Support for Syrian and Iraqi Refugees and Internally Displaced People1 in order to serve as guidanc... more

Download (330)

View PDF (716)

Management of the sick young infant aged up to 2 months. Participant Manual
recommended

World Health Organization WHO (2019) C_WHO

Integrated management of childhood illness. The last update was in the IMCI chart booklet in 2014, but since then there have been significant updates on the management of sick young infant (SYI) aged up to 2 months. This 2019 update of the sick young infant section Management of the sick young infan... more

Download (216)

View PDF (237)

The WHO AWaRe (Access, Watch, Reserve) antibiotic book - Infographics

World Health Organisation (WHO) (2022) C_WHO

Antimicrobial resistance (AMR) is a threat to global health and development and it contributes to millions of deaths worldwide each year. Inappropriate use and overuse of antibiotics are driving an increase in AMR and have a detrimental impact on the effectiveness of these critical medicines. Throug... more

Download (570)

View PDF (828)

WHO Guidelines on tuberculosis infection prevention and control, 2019 update
recommended

World Health Organization (WHO) (2019) C_WHO

The revised guidelines contain recommendations for specific administrative, environmental controls and respiratory protection, following the assessment made by an external group of experts convened as members of the Guideline Development Group. Moreover, these guidelines focus on interventions speci... more

Download (232)

View PDF (524)

Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022
recommended

Pan American Health Organisation PAHO (2022) C_WHO

This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. In recognition of the fact that there are numerous ongoing clinical studies, PAHO will periodically up... more

Download (202)

View PDF (325)

Type 1 diabetes in adults

National Institute for Communicable Disease (NICE) National Institute for Communicable Disease (NICE) (2023) CC2

The document provides quality standards for managing Type 1 diabetes in adults, emphasizing areas like structured education, continuous glucose monitoring (CGM), cardiovascular risk management, and diabetic foot assessment. It aims to improve care processes, reduce complications, and enhance patient... more

External Link

Laboratory techniques in rabies

Rupprecht, C.; Fooks, A,; Abela-Ridder, B. World Health Organization WHO (2018) C_WHO

Rabies has an enormous impact on both agriculture and conservation biology, but its greatest burden is undeniably on public health. As such, routine methods for rapid risk assessment after human exposures to rabies as well as applications for laboratory-based surveillance, production of biologicals ... more

External Link

COVID-19 Infection Prevention and Control Sameeksha
recommended

World Health Organization (WHO), Regional Office for South-East Asia (2021) C_WHO

COVID-19 Infection Prevention and Control Sameeksha (Hindi; review) compiles recent key IPC resources on COVID from scientific journals, WHO guidelines, Ministry of Health and Family Welfare /Government of India guidelines, and trainings and IPC resources. The intended target audience for this inclu... more

Download (278)

View PDF (359)

Ideal Clinic Frameworks and Manual Version 19 (July 2020) - Framework

National Department of Health South Africa (2020) CC

The Ideal Clinic Realisation and Maintenance (ICRM) programme was initiated by the National Department of Health in July 2013 in order to systematically improve primary health care (PHC) facilities and the quality of care they provide. The Ideal Clinic framework/dashboard sets out the standards for ... more

Download (371)

View PDF (391)

WHO good manufacturing practices for pharmaceutical products: main principles

World Health Organization WHO (2014) C_WHO

Licensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status,... more

Download (125)

View PDF (135)

Malaria elimination programme review india 2022

World Health Organisation (WHO) (2023) C_WHO

The document “Malaria Elimination Programme Review, India 2022”, published by the WHO Country Office for India, provides an in-depth assessment of India’s progress toward malaria elimination. It evaluates the structure, implementation, and effectiveness of national and subnational malaria prog... more

Download (52)

View PDF (39)

Advancing equity in diabetes technology

Diabetes Africa (2024) CC

This toolkit suggests several approaches to addressing technology access disparities. At its core is a comprehensive checklist that helps teams systematically evaluate their current practices and identify opportunities for improvement. This structured self-assessment tool spans both team-level a... more

Download (44)

View PDF (32)

Consolidated guidance on tuberculosis data generation and use: module 3: national tuberculosis prevalence surveys

World Health Organization WHO (2025) C_WHO

National tuberculosis (TB) prevalence surveys provide a nationally representative measurement of the burden of TB disease in the population, at a given point in time. Repeat surveys allow assessment of trends and tracking of progress towards national and global targets for reductions in TB disease b... more

Download (44)

View PDF (31)

Integrated Outbreak Analytics Toolkit

Global Outbreak Alerts Response Network GOARN (2025) CC

Integrated Outbreak Analytics (IOA) applies a multidisciplinary approach to understanding outbreak dynamics and to inform outbreak response. It aims to drive comprehensive, accountable, and effective public health and clinical strategies by enabling communities, and national and subnational health a... more

Download (334)

View PDF (614)

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
recommended

World Health Organization WHO (2020) C_WHO

Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries of Asia and Africa. It often affects people with impaired immunity, including people ... more

Download (685)

View PDF (846)

Waterborne Outbreaks of Hepatitis E: recognition, investigation and control

World Health Organization (WHO) (2014) C_WHO

Technical report
This manual aims to provide information about the methods for investigating outbreaks of hepatitis E, and measures for their prevention and control. In addition, the manual gives information about the causative agent – known as the hepatitis E virus (HEV) – its epidemiology... more

Download (472)

View PDF (697)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Laboratory testing for Zika virus and dengue virus infections: interim guidance recommended

Management of the sick young infant aged up to 2 months. Participant Manual recommended

WHO Guidelines on tuberculosis infection prevention and control, 2019 update recommended

Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022 recommended

COVID-19 Infection Prevention and Control Sameeksha recommended

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV recommended